publications GLP-1 Pipeline Update: May 2025 Quarterly view of the GLP-1 pipeline and anticipated indications May 27, 2025 Editorial team Maryam Tabatabai, PharmD Editor-In-Chief Associate Vice...

Maryam Tabatabai, PharmD, vice president of clinical information, and Carole Kerzic, RPh, drug information pharmacist, share more about glucagon-like peptide-1 (GLP-1) receptor agonists in the drug...

Someone holds a GLP-1 pen needle in their hands.

New clinical publication from Prime Therapeutics explores the latest insights for GLP-1s, including trends in spend, drugs in the pipeline, management strategies and more

In the latest episode of the “Pharmacy Friends” podcast, join health outcomes experts for a discussion about Prime’s industry-leading research into persistence and adherence of glucagon-like...

Novo Nordisk’s semaglutide (Wegovy) recently received a U.S. Food and Drug Administration (FDA) accelerated approval for treating metabolic dysfunction-associated steatohepatitis (MASH), the first...

Leading GLP-1 persistence, adherence and clinical outcomes research helps inform health plans and members

publications Quarterly Drug Pipeline: July 2025 Clinical insights and competitive intelligence on anticipated drugs in development July 31, 2025 Editor-in-chief's message Welcome to Prime...